Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes
2013
Fujimoto, Kanta | Hamamoto, Yoshiyuki | Honjo, Sachiko | Kawasaki, Yukiko | Mori, Kanako | Tatsuoka, Hisato | Matsuoka, Atsuko | Wada, Yoshiharu | Ikeda, Hiroki | Fujikawa, Jun | Koshiyama, Hiroyuki
We retrospectively examined the frequency of bladder cancer in Japanese patients with type 2 diabetes in relation to use of pioglitazone. Among a total of 663 patients identified to be taking pioglitazone, 9 had bladder cancer (1.36%). Overall the hazard ratio of 1.75 [95% CI: 0.89–3.45] for pioglitazone for bladder cancer was not significant. However the prevalence of bladder cancer was 2.10% in patients taking pioglitazone for less than 24 months which was significant increased (HR 2.73 [95% CI: 1.11–6.72]).
显示更多 [+] 显示较少 [-]